Regulus Therapeutics Inc

http://www.regulusrx.com/about-regulus/  

dickes plus heute  

8,00

+2,84

+54,89 %


14:07:59

http://www.marketwatch.com/story/...p-c-drug-trial-results-2016-02-17  

http://ir.regulusrx.com/releases.cfm  

 

Regulus Therapeutics Inc. RGLS, +26.11% stock surged nearly 40% in active pre-market trade Wednesday after the company reported positive results from a phase 2 study of a Hepatitis C treatment. Regulus said it will accelerate the Hepatitis C drug's development, given what CEO and President Paul Grint called its "promising potential to shorten treatment regimens." The company's RG-101 drug was injected at the beginning and end of the four-week treatment regimen, with patients also taking anti-viral agents throughout the month-long period. Nearly all of the 38 patients evaluated through eight weeks of follow-up saw the Hepatitis C virus reduced to very low levels, and all the patients saw the same result through 12 weeks of follow-up. Additional results from all 79 patients in the trial should emerge late in the second quarter, the company said.  

http://www.nasdaq.com/de/symbol/rgls/real-time  

Gute Ergebnisse:

LA JOLLA, Calif., Feb. 17, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV).  The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza™.  The study enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni® arm, n=27, Olysio® arm, n=27, Daklinza™ arm, n=25).  Thirty-eight patients have been evaluated through 8 weeks of follow up. Ninety-seven percent of those patients (37/38) had HCV RNA viral load measurements below the limit of quantification.  To date, RG-101 has been generally well tolerated with the majority of adverse events considered mild or moderate, and with no study discontinuations.  For those patients through 12 weeks of follow-up, 100% remained below the limit of quantification (14/14). The primary endpoint analysis (12 week follow up) for all 79 patients in the study are anticipated to be reported in late Q2 2016.  

Neuer Wirkstoff gegen die HCV-Mikro-RNA miR-122

Die leberspezifische Mikro-RNA miR-122 sorgte bereits vor einigen Jahren als vielversprechendes neues Angriffsziel für die Entwicklung eines HCV-spezifischen Medikaments für großes Aufsehen (11). Das damals eingesetzte anti-miR-122-Wirkstoff Miravirsen wurde jedoch von Roche bislang (oder endgültig?) nicht über Phase-II hinaus weiterentwickelt.

Entsprechend groß war nun das Interesse an der GalNAc-konjugierten anti-miR-122-Substanz namens RG-101 der Firma Regulus. Nach einmaliger subkutaner Gabe in unterschiedlicher Dosis lag die HCV-RNA bei insgesamt 6/28 Patienten (1x GT1, 2x GT3 und 3x GT4) noch 28 Wochen später unter der Nachweisgrenze (12). Weitere Studienergebnisse zur Kombination aus RG-101 mit bereits zugelassenen DAAs werden in Kürze erwartet.  

http://www.streetinsider.com/Corporate+News//...didates/12317291.html  

Ganz schön runter! Zum Glück bin ich hier mit ± 0 raus ...  

http://www.finanzen.net/analyse/...c_Hold-Needham__Company_LLC_600945  

 

ich den Absturz für übertrieben!

http://regulusrx.com/programs/clinical-pipeline/  

http://www.nasdaq.com/de/symbol/rgls/real-time  

http://seekingalpha.com/article/...6-results-earnings-call-transcript

 

http://www.finanzen.net/analyse/...bush_Morgan_Securities_Inc__604813  

 

http://www.nasdaq.com/de/symbol/rgls/real-time  

 

1,65USD

+0,15USD

+10,00%

 

http://www.nasdaq.com/de/symbol/rgls/real-time  

 

We also raised $46 million which extends our runway through Q1 2019 providing the necessary capital to get us to keep program milestones all of which I believe position us for longer term success.

https://seekingalpha.com/article/...-results-earnings-call-transcript  

Könnte was werden schauen wir mal bin rein mit SL
Gestern im Amiland gekauft.